FDA approves new flu drug from Durham company
News and Observer
By Jay Price
DURHAM — Research Triangle Park-based BioCryst won U.S. Food and Drug Administration approval Monday to begin selling a new intravenous drug for treating flu.
The drug, Peramivir, will be sold in the United States under the brand name Rapivab. Company officials said it’s the first new flu drug to be approved in 15 years.
Click here to read the full story.